105 related articles for article (PubMed ID: 11705128)
1. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.
Devine EB; Kowdley KV; Veenstra DL; Sullivan SD
Value Health; 2001; 4(5):376-84. PubMed ID: 11705128
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
4. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.
Rivkin AM; Chawla S
Pharmacotherapy; 2005 Jun; 25(6):862-75. PubMed ID: 15927905
[TBL] [Abstract][Full Text] [Related]
5. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
[TBL] [Abstract][Full Text] [Related]
7. [Incidence of haemolytic anaemia during combination therapy of chronic hepatitis C with interferon alpha-2b and ribavirin].
Adamek A; Adamek J; Juszczyk J
Pol Merkur Lekarski; 2004 Nov; 17(101):443-5. PubMed ID: 15754628
[TBL] [Abstract][Full Text] [Related]
8. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.
Krishnan SM; Dixit NM
PLoS Comput Biol; 2011 Feb; 7(2):e1001072. PubMed ID: 21304937
[TBL] [Abstract][Full Text] [Related]
9. The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
Devine EB; Cross JT; Kowdley KV; Sullivan SD
Curr Med Res Opin; 2007 Jun; 23(6):1463-72. PubMed ID: 17559739
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
11. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
Kasahara A
J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
[No Abstract] [Full Text] [Related]
12. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
J Gastroenterol; 2004 Nov; 39(11):1090-4. PubMed ID: 15580403
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
14. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
[TBL] [Abstract][Full Text] [Related]
15. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
Itoh Y; Okanoue T
J Gastroenterol; 2004 Jul; 39(7):704-5. PubMed ID: 15293148
[No Abstract] [Full Text] [Related]
16. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
17. Factors contributing to ribavirin-induced anemia.
Nomura H; Tanimoto H; Kajiwara E; Shimono J; Maruyama T; Yamashita N; Nagano M; Higashi M; Mukai T; Matsui Y; Hayashi J; Kashiwagi S; Ishibashi H
J Gastroenterol Hepatol; 2004 Nov; 19(11):1312-7. PubMed ID: 15482540
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Yachimski P; Chung RT
AIDS Read; 2004 Oct; 14(10):568-9. PubMed ID: 15510393
[No Abstract] [Full Text] [Related]
20. Anemia during treatment of hepatitis C in HIV-infected patients.
Lo Re V; Kostman JR
AIDS Read; 2004 Oct; 14(10):555-7, 562, 565-71. PubMed ID: 15510392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
